Oncolys BioPharma, Inc. (4588) AI Stock Analysis

• Market Cap: ¥15.43B
• Dividend Yield: N/A
• Average Volume (3M): 680.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: 11.93%
• EPS Growth: 15.04%
• Country: JP
• Employees: 40
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): -32.66
• Shares Outstanding: 24,961,600
• 10 Day Avg. Volume: 1,072,830
• 30 Day Avg. Volume: 680,786
• PEG Ratio: 0.26
• Price to Book (P/B): 4.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: ¥584.00 ▼(-4.73%Downside)

The overall score reflects the significant financial challenges Oncolys BioPharma faces, including declining revenues and negative cash flows. Although there are some short-term technical strengths, the long-term technical indicators are weak. The valuation is unattractive due to the negative P/E ratio and lack of dividends, highlighting the risks in investing in this stock.

Oncolys BioPharma, Inc. Business Overview & Revenue Model

Company Description

Oncolys BioPharma, Inc. is a Japan-based biotechnology company focused on the development and commercialization of innovative therapeutics for oncology and infectious diseases. The company leverages its proprietary technology platforms to develop novel oncolytic viruses and antiviral agents, aiming to provide cutting-edge treatment options for patients. Oncolys BioPharma's core products include investigational drugs that are in various stages of clinical development.

How the Company Makes Money

Oncolys BioPharma, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company earns income through licensing agreements with pharmaceutical partners, which may include upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Additionally, Oncolys may receive research and development funding from collaborations with other biotech and pharmaceutical companies. Strategic partnerships are a significant factor in the company's revenue generation, allowing it to leverage the expertise and resources of larger organizations to advance its drug candidates through clinical trials and into the market.

Oncolys BioPharma, Inc. Financial Statement Overview

Summary

Oncolys BioPharma, Inc. faces serious financial challenges characterized by declining revenues, persistent losses, and negative cash flows. The balance sheet shows strong equity, but the inability to achieve profitability and positive cash flow poses significant risks to long-term viability.

Income Statement

Oncolys BioPharma, Inc. has experienced significant revenue decline, with a drop from 2022 to 2023 and further to 2024. The company has consistently operated at a loss, with negative EBIT and net income margins, reflecting challenges in scaling profitable operations.

Balance Sheet

The company maintains a healthy equity position with a strong equity ratio, indicative of solid capitalization. However, the continued losses affect return on equity negatively. While debt levels are manageable, the lack of profitability is concerning for long-term stability.

Cash Flow

Operating and free cash flow have remained negative, indicating ongoing operational cash burn. Despite positive financing cash flow, likely from fundraising, the inability to generate positive cash flow from operations is a critical risk.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
31.38M	63.04M	976.18M	642.49M	314.18M
	Gross Profit
31.38M	30.61M	338.49M	198.80M	236.11M
	EBIT
-1.68B	-1.93B	-1.20B	-1.45B	-1.67B
	EBITDA
-1.68B	-1.93B	-1.14B	-1.60B	-2.08B
	Net Income Common Stockholders
-1.68B	-1.94B	-1.15B	-1.62B	-2.10B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.41B	1.53B	1.71B	3.45B	2.07B
	Total Assets
3.20B	2.04B	2.65B	4.29B	2.80B
	Total Debt
324.64M	315.17M	393.66M	503.47M	525.08M
	Net Debt
-1.84B	-972.59M	-1.32B	-2.95B	-1.54B
	Total Liabilities
446.65M	566.50M	491.69M	697.88M	793.09M
	Stockholders Equity
2.75B	1.47B	2.16B	3.59B	2.00B
Cash Flow		Free Cash Flow
-2.02B	-1.34B	-1.72B	-1.74B	-1.47B
	Operating Cash Flow
-2.02B	-1.34B	-1.72B	-1.74B	-1.47B
	Investing Cash Flow
-4.71M	-5.39M	20.12M	-942.00K	-37.58M
	Financing Cash Flow
2.88B	1.14B	-113.83M	3.09B	242.26M

Oncolys BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 613.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Positive. The current price of 613 is above the 20-day moving average (MA) of 594.00, above the 50-day MA of 562.94, and above the 200-day MA of 609.37, indicating a bullish trend. The MACD of 19.16 indicates Negative momentum. The RSI at 54.74 is Neutral, neither overbought nor oversold. The STOCH value of 16.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4588.

Oncolys BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	68 Neutral	¥14.42B	284.55		0.69%	-13.57%	-106.11%
4579	62 Neutral	¥15.24B	―		―	57.13%	-66.39%
4888	55 Neutral	¥13.68B	―		―	256.62%	82.54%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
4583	48 Neutral	¥11.16B	―		―	14.41%	27.42%
4599	47 Neutral	¥19.88B	―		―	-100.00%	-1079.89%
4588	44 Neutral	¥15.43B	―		―	11.93%	15.04%

Oncolys BioPharma, Inc. Corporate Events

Oncolys BioPharma Reports Decline in Q1 2025 Financial Results

Oncolys BioPharma Inc. reported its financial results for the first quarter of 2025, showing a significant decline in net sales and profits compared to the previous year. The company’s financial position weakened, with total assets and equity ratio decreasing, reflecting challenges in maintaining profitability and market stability.